- Home
- AMLX vs SONO Comparison
AMLX vs SONO Comparison
Compare AMLX & SONO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | SONO |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AMLX | SONO |
|---|---|---|
| Price | $14.54 | $15.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $21.56 | $19.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ 0.52 |
| Revenue | $380,786,000.00 | ★ $1,443,276,000.00 |
| Revenue This Year | N/A | $5.04 |
| Revenue Next Year | N/A | $6.53 |
| P/E Ratio | ★ N/A | $29.73 |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $4.86 | $10.12 |
| 52 Week High | $18.61 | $19.82 |
Technical Indicators
Market Signals| Indicator | AMLX | SONO |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 49.92 |
| Support Level | $12.32 | $14.44 |
| Resistance Level | $15.37 | $15.69 |
| Average True Range (ATR) | 0.79 | 0.69 |
| MACD | 0.13 | -0.11 |
| Stochastic Oscillator | 81.78 | 36.63 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
About SONO Sonos Inc.
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.